UK – NICE backs NHS use of Lilly’s Olumiant in eczema

Eli Lilly’s Olumiant has received a UK National Health and Care Excellence (NICE) recommendation for the treatment of moderate-to-severe atopic dermatitis (atopic eczema) in adults.

NICE has backed use of Olumiant (baricitinib) for patients whose disease has not responded to at least one systemic immunosuppressant, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil or where these are not suitable.

Lilly agreed a confidential commercial agreement with NICE, meaning the NHS will receive Olumiant at a discounted price.

Olumiant is an oral JAK inhibitor that acts as an immunosuppressant and blocks the action of JAK1 and JAK2. These enzymes play a key role in the process of inflammation and inflammatory diseases like atopic dermatitis…